Not intended for UK- or UK-based media
- Grant established by Merck recognizes pioneering research in
personalized treatment of solid tumors
- Winners selected by internationally renowned oncologists
from 405 applications representing 49 countries
DARMSTADT, Germany,
Oct. 10, 2016 /CNW/ - Merck, a
leading science and technology company, today announced the
recipients of the 2016 Grant for Oncology Innovation (GOI), who
will share a €1 million grant to progress their respective research
initiatives. The winners were formally awarded yesterday evening at
an award presentation coinciding with the 2016 annual European
Society for Medical Oncology (ESMO) Congress in Copenhagen, Denmark.
(Photo: http://photos.prnewswire.com/prnh/20161006/415895 )
The three winning proposals, which focus on breast cancer,
colorectal cancer and lung cancer, were selected from a total of
405 applications representing 49 countries, following a
comprehensive review by an expert scientific steering committee
made up of internationally renowned oncologists.
The 2016 GOI winners are:
- Alberto Bardelli, University of
Torino, Italy, for his proposal:
'Heterogeneity and clonal evolution as a therapeutic opportunity
for colorectal cancers'
- Enriqueta Felip, Vall d'Hebron
Institute of Oncology, Spain, for
her proposal: 'New technologies for new treatments: liquid biopsy
meets immunotherapy'
- Dr Dongxu Liu, Auckland University of Technology,
New Zealand for his proposal: 'How
does SHON* expression in tumors determine the efficacy of endocrine
therapy in breast cancer?'
"The Grant for Oncology Innovation is an example of Merck's
commitment to scientific innovation in oncology. We are proud to
support pioneering work that pushes the boundaries of creativity
and science in order to deliver transformative innovation with a
potential to improve the lives of cancer patients in the near-term
future," said Dr Steven Hildemann,
Global Chief Medical Officer and Head of Global Medical and Safety
at Merck´s Biopharma business. "We are honored to recognize these
talented and inspiring researchers and to play a role in enabling
these innovative projects to become a reality."
These awards mark the third successful year for GOI. Every year,
Merck offers grants totaling €1 million through the GOI program.
More information about the GOI can be found online at:
http://www.grantforoncologyinnovation.org
Merck is committed to rewarding innovation and new thinking that
could further advance the field of medicine. To learn more about
the variety of innovation grants that Merck offers, visit:
http://www.merckgroup.com/en/innovation/grants_awards_initiatives/innovation_grants_awards_initiatives.html
*Secreted hominoid-specific oncogene (SHON), an
estrogen-regulated gene.
For further information and press materials please
visit:http://www.merckgroup.com/media-center-oncology
All Merck Press Releases are distributed by e-mail at the same
time they become available on the Merck Website. Please go to
http://www.merckgroup.com/subscribe to register online, change your
selection or discontinue this service.
About Merck
Merck is a leading science and technology company in healthcare,
life science and performance materials. Around 50,000 employees
work to further develop technologies that improve and enhance life
- from biopharmaceutical therapies to treat cancer or multiple
sclerosis, cutting-edge systems for scientific research and
production, to liquid crystals for smartphones and LCD televisions.
In 2015, Merck generated sales of € 12.85 billion in 66
countries.
Founded in 1668, Merck is the world's oldest pharmaceutical and
chemical company. The founding family remains the majority owner of
the publicly listed corporate group. Merck, Darmstadt, Germany holds the global rights to the Merck
name and brand. The only exceptions are the United States and Canada, where the company operates as EMD
Serono, MilliporeSigma and EMD Performance Materials.
(Logo: http://photos.prnewswire.com/prnh/20151207/293543LOGO
)
SOURCE Merck